ATE500244T1 - 1,5-substituierte indol-2-yl amidderivative - Google Patents

1,5-substituierte indol-2-yl amidderivative

Info

Publication number
ATE500244T1
ATE500244T1 AT06830046T AT06830046T ATE500244T1 AT E500244 T1 ATE500244 T1 AT E500244T1 AT 06830046 T AT06830046 T AT 06830046T AT 06830046 T AT06830046 T AT 06830046T AT E500244 T1 ATE500244 T1 AT E500244T1
Authority
AT
Austria
Prior art keywords
amide derivative
substituted indol
indol
substituted
amide
Prior art date
Application number
AT06830046T
Other languages
English (en)
Inventor
Matthias Nettekoven
Jean-Marc Plancher
Hans Richter
Olivier Roche
Valerie Runtz-Schmitt
Sven Taylor
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37814240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE500244(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE500244T1 publication Critical patent/ATE500244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06830046T 2005-11-30 2006-11-20 1,5-substituierte indol-2-yl amidderivative ATE500244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05111478 2005-11-30
PCT/EP2006/068655 WO2007062999A2 (en) 2005-11-30 2006-11-20 1,5-substituted indol-2-yl amide derivatives

Publications (1)

Publication Number Publication Date
ATE500244T1 true ATE500244T1 (de) 2011-03-15

Family

ID=37814240

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06830046T ATE500244T1 (de) 2005-11-30 2006-11-20 1,5-substituierte indol-2-yl amidderivative

Country Status (18)

Country Link
US (1) US7745479B2 (de)
EP (1) EP1957479B1 (de)
JP (1) JP4879997B2 (de)
KR (1) KR101124156B1 (de)
CN (1) CN101316840B (de)
AR (1) AR057989A1 (de)
AT (1) ATE500244T1 (de)
AU (1) AU2006319234B2 (de)
BR (1) BRPI0619268A2 (de)
CA (1) CA2630314A1 (de)
DE (1) DE602006020482D1 (de)
ES (1) ES2359739T3 (de)
IL (1) IL191314A (de)
NO (1) NO20082136L (de)
RU (1) RU2008126391A (de)
TW (1) TWI333490B (de)
WO (1) WO2007062999A2 (de)
ZA (1) ZA200804301B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063000A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
EP1968967B1 (de) * 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl-indolyl-methanon-derivate zur verwendung als h3-modulatoren
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
WO2008083124A1 (en) * 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
US7507736B2 (en) * 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
JP5544296B2 (ja) * 2007-11-16 2014-07-09 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
ES2553340T3 (es) 2007-12-12 2015-12-07 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
JP5658138B2 (ja) * 2008-04-23 2015-01-21 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害の処置のためのカルボキサミド化合物
US9394294B2 (en) * 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) * 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
JP6049615B2 (ja) 2010-07-23 2016-12-21 デマークス・インコーポレイテッドＤｅｍｅｒｘ，Ｉｎｃ． ノリボガイン組成物
EP2481740B1 (de) 2011-01-26 2015-11-04 DemeRx, Inc. Verfahren und Zusammensetzungen zur Herstellung von Noribogain aus Voacangin
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2851087C (en) * 2011-10-07 2019-09-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
EP2788003A4 (de) 2011-12-09 2015-05-27 Demerx Inc Phosphatester von noribogain
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
CA2896133A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
PT3071203T (pt) 2013-11-18 2021-03-11 Forma Therapeutics Inc Composições de tetra-hidroquinolina como inibidores de bromodomínio bet
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
CN105523986A (zh) * 2015-12-30 2016-04-27 江汉大学 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法
JP7230240B2 (ja) 2019-12-11 2023-02-28 富士フイルム株式会社 半月板投影面設定装置、方法およびプログラム
CN115340460B (zh) * 2022-09-21 2024-07-16 江西亚太科技发展有限公司 一种Reissert吲哚合成反应中间体的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE69916288T2 (de) 1998-08-14 2005-03-24 F. Hoffmann-La Roche Ag Lipasehemmer und chitosan enthaltende arzneimittel
BR9912980B1 (pt) 1998-08-14 2013-10-22 Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma
CZ301366B6 (cs) 1999-03-29 2010-02-03 F. Hoffmann-La Roche Ag 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
EP1554260A1 (de) * 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivate als h3 rezeptor liganden
ES2306170T3 (es) 2004-06-21 2008-11-01 F. Hoffmann-La Roche Ag Derivados de indol como antagonistas redeptores de histamina.
EP1968967B1 (de) * 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl-indolyl-methanon-derivate zur verwendung als h3-modulatoren
US7507736B2 (en) * 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives

Also Published As

Publication number Publication date
JP4879997B2 (ja) 2012-02-22
KR101124156B1 (ko) 2012-03-23
US20070123515A1 (en) 2007-05-31
ZA200804301B (en) 2009-04-29
AU2006319234A1 (en) 2007-06-07
US7745479B2 (en) 2010-06-29
WO2007062999A2 (en) 2007-06-07
IL191314A (en) 2012-06-28
CN101316840B (zh) 2012-08-08
CN101316840A (zh) 2008-12-03
TW200804340A (en) 2008-01-16
AR057989A1 (es) 2008-01-09
KR20080076980A (ko) 2008-08-20
AU2006319234B2 (en) 2012-01-19
NO20082136L (no) 2008-06-30
EP1957479A2 (de) 2008-08-20
CA2630314A1 (en) 2007-06-07
TWI333490B (en) 2010-11-21
RU2008126391A (ru) 2010-01-10
JP2009517433A (ja) 2009-04-30
EP1957479B1 (de) 2011-03-02
DE602006020482D1 (de) 2011-04-14
BRPI0619268A2 (pt) 2011-09-20
WO2007062999A3 (en) 2007-07-26
ES2359739T3 (es) 2011-05-26

Similar Documents

Publication Publication Date Title
ZA200804301B (en) 1,5-substituted indol-2-yl amide derivatives
NL300935I2 (nl) guselkumab.
HUS1900034I1 (hu) 6,7-telítetlen-7-karbamoil-szubsztituált morfinán-származékok
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
EP1928828A4 (de) Anthracenderivat
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
ATE506362T1 (de) 1-aza-bicycloä3.3.1ünonane
ATE500227T1 (de) Amidderivate
ITMO20050327A1 (it) Mola perfezionata
FR2893200B1 (fr) Alternateur.
DE502006001027D1 (de) Cyanuraten
ATE517878T1 (de) Substituierte 5-phenyl-3,6-dihydro-2-oxo-6h-ä1,3, 4üthiadiazine
ES1061567Y (es) "conjunto rodadero"
TWI315670B (en) Substituted aryl 1,4-pyrazine derivatives
EP1867636A4 (de) Pyridylmethylsulfonderivat
DE602006014973D1 (de) Neuartige cercosporamidderivate
DE502006004816D1 (de) Verstellbeschlag
FI20055624A0 (fi) Ilmakammio
EP1935879A4 (de) Substituiertes cycloalkenderivat
ATE538121T1 (de) 1,5,6-substituierte-2-oxo-3-cyano-1,6a- diazatetrahydrofluoranthene als antiinfektionsmittel
DK1960510T3 (da) Ammoniakspecifik 5'-xmp-aminasemutant
EP1940415A4 (de) 19,23,24,25,26,27-hexanor-1alpha-hydroxyvitamin d3
DE102005063244A8 (de) Modifiziertes 2-Nitroimidazol-Derivat
EP1915490A4 (de) Duchführungsanordnung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1957479

Country of ref document: EP